ArticleJournal of contemporary brachytherapy2025
Diaphragm and lung dose in liver high-dose-rate interstitial brachytherapy: A dosimetry and toxicity report.
Article in Journal of contemporary brachytherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Beyond TG‑43: A PRISMA-based systematic review on model-based dose-calculation algorithms in brachytherapy.Journal of applied clinical medical physics · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study was to retrospectively analyze and report on dose-volume and clinical toxicity of liver high-dose-rate interstitial brachytherapy (HDR-IBT) used in diaphragm and lung tissue. Material and methods: Computed tomography (CT)-based liver HDR-IBT using Oncentra Brachy treatment planning system (TPS) plans of patients with malignant liver tumor (MLT) from September 2018 to June 2023 were reviewed to identify patients, whose diaphragm and lung tissue were within 100% prescription isodose. These organs at risk (OARs) were contoured in axial CT slices. Maximum point dose (D Results: The analysis included 27 patients with 43 and 36 MLTs, whose 100% prescription isodose of liver HDR-IBT plan was within diaphragm and lung tissue. Median prescription dose was 25 Gy (range, 15-25 Gy) in single-fraction. Median D Conclusions: This is the first publication reporting diaphragm and lung tissue dose-volume and clinical toxicity in liver HDR-IBT. Small volume of diaphragm and lung tissue tolerated extreme high radiation doses [5 times of stereotactic body radiotherapy (SBRT) range in single fraction] without clinically significant toxicity. A standardized reporting for diaphragm and lung dose volume is needed for future liver HDR-IBT studies. The results of the current study can be employed in future for expanded indication of brachytherapy, such as CT-guided trans-thoracic lung brachytherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.